Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mathym is a French nanotechnology company specializing in the development and industrialization of innovative colloidal solutions for the healthcare and optoelectronics sectors. Founded in 2013 and headquartered in Lyon, the company focuses on the synthesis of high-refractive index and radiopaque nanoparticles, including zirconia, ytterbium fluoride, and cerium oxide. Their proprietary liquid-phase synthesis platform enables the production of ultra-small, non-agglomerated particles that enhance the mechanical and optical properties of dental composites and biomedical materials. In 2019, Mathym was acquired by Baikowski, a global leader in high-purity alumina, to strengthen its position in the high-tech materials market. The company continues to operate as a specialized subsidiary, providing customized nanomaterials for global industrial partners.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MATHYM.